Urinary cell cycle arrest biomarker (TIMP-2)·(IGFBP7) in patients with hepatorenal syndrome
Background: Patients with hepatorenal syndrome carry a high short-term mortality. Early diagnosis and treatment are essential for patients’ outcome. Nevertheless diagnosis of HRS remains difficult. First-line therapy terlipressin is often associated with severe complications. Biomarkers become more...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
22 Aug 2019
|
| In: |
Biomarkers
Year: 2019, Volume: 24, Issue: 7, Pages: 692-699 |
| ISSN: | 1366-5804 |
| DOI: | 10.1080/1354750X.2019.1652347 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1080/1354750X.2019.1652347
|
| Author Notes: | Chengcheng Christine Zhang, Diane Alix Artémis Hoffelt, Uta Merle |
| Summary: | Background: Patients with hepatorenal syndrome carry a high short-term mortality. Early diagnosis and treatment are essential for patients’ outcome. Nevertheless diagnosis of HRS remains difficult. First-line therapy terlipressin is often associated with severe complications. Biomarkers become more on focus for an early diagnosis.Objective: The aim of this study was to test the diagnostic accuracy of urinary [TIMP-2]·[IGFBP7] for HRS patients and prognostic value for therapy responding patients.Material and methods: NephroCheck® measures urinary concentrations of TIMP-2 and IGFBP-7, both indicating stress of renal cells and associated with induction of cell cycle arrest. 22 HRS patients and 30 patients with normal kidney function were included. [TIMP-2]·[IGFBP7] was measured using NephroCheck®. HRS patients receiving terlipressin were also examined.Results: [TIMP-2]·[IGFBP7] values did not differ significantly (1.3 ± 2.09 vs. 1.03 ± 1.03; p = 0.55). Furthermore, there was no significant difference of [TIMP-2]·[IGFBP7] regarding response of terlipressin (1.32 ± 2.39 vs. 0.81 ± 1.05; p = 0.56). Low [TIMP-2]·[IGFBP7] values were significantly associated with higher mortality (p = 0.01).Conclusions: The results of this study suggest that [TIMP-2]·[IGFBP7] is not suitable for diagnostic of HRS and prediction of therapy response, but there might be evidence for prognostic value of [TIMP-2]·[IGFBP7] in regard to mortality of liver cirrhosis patients. |
|---|---|
| Item Description: | Gesehen am 11.11.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1366-5804 |
| DOI: | 10.1080/1354750X.2019.1652347 |